Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03956680 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
A Phase 1 study of Advanced Solid Cancers, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 5
- Study locations
NCT03956680 is a Phase 1 study of Advanced Solid Cancers that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 54 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT03956680, a Phase 1 study of Advanced Solid Cancers, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in participants with cancers that have failed to respond to T cell checkpoint inhibiting antibodies.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG BMS-986301
Study Locations (5)
Illinois
- Local Institution - 0003 - Chicago
Missouri
- Local Institution - 0005 - St Louis
Pennsylvania
- Local Institution - 0006 - Pittsburgh
Tennessee
- Local Institution - 0002 - Nashville
Ontario
- Local Institution - 0001 - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03956680
The ClinicalTrials.gov registry entry for NCT03956680 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Cancers appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT03956680 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03956680 about?
NCT03956680 is a clinical study titled "An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers". The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in participants with cancers ...
What is the current status of trial NCT03956680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-03-26. Estimated completion is 2024-04-24.
What conditions does trial NCT03956680 study?
This clinical trial studies the following conditions: Advanced Solid Cancers.
What interventions are being tested in trial NCT03956680?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-986301 (DRUG).
Who is sponsoring clinical trial NCT03956680?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03956680 being conducted?
This trial has 5 study locations across Illinois, Missouri, Pennsylvania, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.